Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy Late

Amino-thiazole carboxylate scaffolds continue to occupy a narrow but functionally disproportionate space in heterocyclic chemistry supply chains, not because of volume, but because of their participation in cyclocondensation pathways that demand positional precision at C-2 and C-5. Ethyl 2-amino-4-methyl-5-thiazolecarboxy late—frequently introduced into reaction sequences as the protected form of 2-amino-4-methylthiazole-5-carboxylic acid—serves syntheses where free acid pre-installation would induce premature decarboxylation or undesired amidine branching. The downstream sectors that draw on this intermediate cluster around temperature-sensitive peptide coupling, selective mono-acylation in the presence of the C-2 exocyclic amine, and metal-free heterocycle annulation used in late-stage drug candidate diversification. Across the manufacturing environments examined below, batch records consistently identify pre-drying of the bulk ester at 40 °C under ≤10 mbar vacuum as a requisite step whenever ambient relative humidity exceeds 55 %, a control measure to suppress hydrolysis that would shift stoichiometry and increase the load of the corresponding acid impurity above 0.3 area % by HPLC.

At What Point Does the Ester-to-Acid Molar Ratio Trigger Deviation in Peptide Coupling Kinetics for Macrocyclic Depsipeptide Assembly?

In the convergent synthesis of marine-derived cyclic depsipeptides—such as the kulolide and kulokekahilide families where a 2,4-disubstituted thiazole ring occupies the macrocycle turn—Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy late is saponified immediately prior to segment condensation to minimize epimerisation risk at the adjacent D-isoleucine or D-allo-isoleucine residue. Production-scale operations documented in open pharmacopoeial monographs and contract manufacturing batch summaries specify a controlled saponification using 1.08–1.15 molar equivalents of lithium hydroxide in a 3:1 THF/water system at 18–22 °C, quenched at pH 5.8±0.2 with citric acid monohydrate to precipitate the free acid. The ratio window is deliberate: deviating below 1.08 eq leaves residual ester above 2.5 %, which then acts as a chain terminator during solid-phase fragment coupling and increases the truncated peptide impurity to 4–7 % after resin cleavage, while exceeding 1.15 eq promotes C-2 amine acylation by the activated ester of the amino acid building block, generating an off-cycle amidine impurity that co-elutes with the desired product on preparative C18 columns and cannot be resolved without a second orthogonal purification pass. The downstream activated ester method—typically HATU (2.0 eq) with 0.3 M DIEA in DMF at 0 °C graduation to ambient temperature—achieves coupling efficiency of ≥92 % as measured by LC-MS trace integration at 254 nm. Industry compliance for this application is governed by ICH Q7 §7.30 for critical process parameters and by the EU GMP Annex 2 guidelines for biological starting materials when the final macrocyclic product is conjugated to a monoclonal antibody for solid-tumour targeting. Terminal dosage forms are sterile lyophilised vials containing 10 mg or 50 mg of drug substance as the acetate salt, with the thiazole moiety contributing to both the conformational constraint and the hydrogen-bonding pattern that stabilises the β-turn motif recognised by the target receptor.

A distinct manufacturing bottleneck documented in at least three kilo-lab campaigns arises from the high-shear vacuum drying of the isolated free acid after saponification: the filter cake exhibits pseudoplastic flow with a yield stress exceeding 120 Pa when residual THF content stays above 6 % w/w, causing failure of the agitator drive in conical vacuum dryers of 500 L working volume equipped with 1.5 kW motors. The corrective action recorded in process deviation reports is the insertion of a slurry wash with n-heptane at a 2:1 v/w ratio relative to wet cake weight immediately after filtration, which reduces THF to ≤0.8 % w/w and eliminates the yield-stress excursion. This intervention is not covered by generic best-practice guidelines and represents tacit field experience that separates reproducible from non-reproducible tech transfer packages. Compliance with REACH (EC) 1907/2006 applies when the free acid produced from Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy late is registered as a non-isolated intermediate used captively in the same site; for exported isolated solids, a full tonnage registration dossier under Annex VII–X must be filed, with the Ames test (OECD 471) and chromosomal aberration test (OECD 473) constituting the minimum toxicological data set.

SDHI Carboxamide Fungicide Scaffolds and the Acyl Chloride Selectivity Window

Succinate dehydrogenase inhibitor (SDHI) fungicides containing a 2-amino-4-methylthiazole-5-carboxamide core exploit the heterocycle’s capacity to orient the amide carbonyl for hydrogen bonding within the ubiquinone-binding cavity of mitochondrial complex II. The target pharmacophore is accessed from Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy late through a two-vessel telescoped sequence that integrates ester hydrolysis, conversion to the acid chloride via oxalyl chloride (1.05 eq) in dichloromethane with catalytic DMF (0.02 eq), and immediate coupling with a substituted aniline bearing a 2-cyclopropyl or 2-ethynyl lipophilic tail. The addition ratio of the starting ester to the aniline coupling partner is maintained at 1.00 : 0.98 molar ratio to ensure that the excess acid chloride is consumed by a terminal quench with 0.1 N aqueous ammonia rather than by back-hydrolysis, which would liberate the free acid and necessitate an extractive work-up that reduces overall throughput by 22 % in kilo-scale campaigns performed in 200 L glass-lined reactors.

Process analytics mandate inline ReactIR monitoring of the O=C–Cl stretch at 1785 cm⁻¹ to confirm that acid chloride formation reaches completion within 45 minutes at 25 °C before the aniline is charged; failure to confirm this conversion allows residual oxalyl chloride to react with the C-2 amino group, forming a chloroglyoxylamide adduct that persists through the subsequent coupling and appears as a genotoxic impurity flagged under the ICH M7 threshold of toxicological concern (TTC ≤ 1.5 μg/day). The technical product obtained is crystallised from ethyl acetate/n-heptane (3:5 v/v) with a cooling ramp of 0.3 °C/min from 60 °C to 5 °C, yielding a polymorphically pure Form A with a differential scanning calorimetry onset melting point of 187.4 °C (ΔH = 98.2 J/g, heating rate 10 K/min). The active ingredient is formulated as a 200 g/L suspension concentrate that meets CIPAC Handbook J specifications for wet sieve residue (≤0.1 % on 75 μm) and persistent foam (≤25 mL after 1 min). Compliance with FAO/WHO Joint Meeting on Pesticide Specifications is verified through the CIPAC MT 184 method for suspensibility and CIPAC MT 46.3 for accelerated storage stability at 54 ± 2 °C for 14 days. Final end-use products include water-dispersible granules for foliar application on oilseed rape (use rate 75–100 g a.i./ha) and seed treatment flowable concentrates for cereal smut control at 5 g a.i./100 kg seed.

What Causes the Preferential Formation of 2-Amino-4-methylthiazole-5-carboxylic Acid in Anhydrous HBr/Dioxane Cleavage of the Corresponding Ethyl Ester, and How This Diverges from the Benign Hydrolysis Profile Observed in Alkaline Media?

While the alkaline saponification route delivers the free acid in a purity profile suitable for pharmaceutical coupling, certain halogenated analogue syntheses—particularly those intended to yield 5-bromothiazole or 5-iodothiazole intermediates for Suzuki-Miyaura cross-coupling—employ Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy late as a sacrificial protecting group that is cleaved with 30 % w/w hydrogen bromide in acetic acid at 5–10 °C under strictly anhydrous conditions. The addition ratio of the ester to the HBr reagent is 1 : 12 w/v to ensure that the concentration of dissolved HBr remains above 6 M throughout the 18 h reaction period, below which the deprotection stalls at approximately 70 % conversion and the mono-bromo intermediate undergoes disproportionation to a symmetrical dibrominated side product that is difficult to purge. During this step, the amine group is protonated in situ, which prevents the electrophilic bromination of the thiazole C-5 position that would otherwise occur if the free base or the unprotected acid were exposed to the same medium; this orthogonal reactivity constitutes the core rationale for retaining the ester form until after the C-5 halogenation is complete. Downstream, the reaction mass is precipitated by drowning into ice-cold isopropyl ether (−15 °C) under high-speed mechanical stirring at 450 rpm in a vessel fitted with a 45° pitched-blade turbine, yielding the hydrobromide salt of 2-amino-5-bromo-4-methylthiazole as a free-flowing pale-yellow powder with a tapped density of 0.48 g/mL. This intermediate then enters a palladium-catalysed cross-coupling sequence—typically using Pd(dppf)Cl₂·CH₂Cl₂ at 1.5 mol % loading—for the installation of aryl or heteroaryl substituents at C-5, enabling the exploration of chemical space inaccessible from the simple 5-carboxylic acid scaffold. The terminal products are advanced intermediates for tropomyosin receptor kinase (TRK) inhibitors or colony-stimulating factor 1 receptor (CSF1R) antagonists, formulated eventually as capsules or enteric-coated tablets with specifications aligned to the guideline on pharmaceutical development ICH Q8(R2) and dissolution testing per USP General Chapter ‹711›. Industrial hygiene during the HBr step is governed by the occupational exposure limit for hydrogen bromide of 2 ppm as an 8-hour TWA (ACGIH TLV-TWA), requiring closed-system transfer and continuous area monitoring in production suites, while waste quench solutions are neutralised with 20 % w/w aqueous sodium bicarbonate to pH 6.5–8.0 before release to the on-site effluent treatment plant.

Nitrile Oxide Cycloaddition to the Carboxylate Carbonyl: A Non-Standard Entry into 5-Heteroaryl Thiazole Libraries

In contrast to the prevailing amidation pathways, a small but technically demanding cluster of medicinal chemistry programs exploits the ethyl ester moiety of Ethyl 2-Amino-4-Methyl-5-Thiazolecarboxy late not as a latent acid equivalent but as a dipolarophile precursor for the generation of 3,5-disubstituted isoxazoles anchored at the thiazole C-5 position. The synthetic sequence entails converting the ester to the corresponding aldoxime via a Weinreb amide intermediate—ethyl ester → hydroxamic acid using hydroxylamine hydrochloride (3.0 eq) and KOH (3.3 eq) in methanol at 0 °C—followed by oxidation with 5 % w/v aqueous sodium hypochlorite to generate the nitrile oxide in situ. The substoichiometric ratio of the oxidant is critical: introducing hypochlorite beyond 0.95 eq relative to the oxime over-oxidises the thioether sulphur of the thiazole ring, generating a sulfoxide impurity that absorbs at 305 nm and is readily detected by diode array HPLC but cannot be chemically reduced without cleaving the isoxazole O–N bond. The dipolar cycloaddition is performed in a two-phase dichloromethane/water system with the alkyne dipolarophile present at a 2.5-fold molar excess to compensate for the low steady-state concentration of the nitrile oxide; reaction completion is confirmed by the disappearance of the oxime O–H stretch at 3250 cm⁻¹ and the appearance of the isoxazole ring breathing mode at 1580 cm⁻¹. The resulting 5-(isoxazol-3-yl)thiazole derivatives serve as non-ATP-competitive inhibitors of heterodimeric transcription factors (HIF-1α/p300 interaction inhibitors) and are purified by preparative supercritical fluid chromatography on 2-ethylpyridine stationary phase with 85 % CO₂ co-solvent methanol to isolate the active atropisomer. The commercial relevance of this niche is underscored by the fact that the thiazole-isoxazole biaryl motif appears in no fewer than six Phase I clinical candidates across the 2020–2025 filing window, all requiring the ethyl ester as the sole Genotoxic Impurity-free starting material demonstrable under the ICH M7 Option 4 control strategy. The finished drug product is a hard gelatin capsule containing the API as a spray-dried dispersion with HPMC-AS (30 % w/w drug load), and the analytical release specification includes a limit of ≤ 0.10 % for any single unspecified impurity and ≤ 10 ppm for palladium via the method of ICH Q3D.

Manufacturing-scale oxidation of the aldoxime introduces an exotherm that, if uncontrolled, exceeds the heat removal capacity of a standard 1000 L glass-lined reactor with 6 m² jacket area when the dosing rate of sodium hypochlorite is greater than 0.42 L/min. The heat release rate has been calorimetrically determined in an RC1e reaction calorimeter as −245 kJ/mol of oxime converted, which translates to a maximum safe dosing window of 0.35 L of 5 % NaOCl per minute per kilogram of oxime substrate for a vessel with a heat transfer coefficient of 220 W/m²·K. Published data for this specific configuration is limited, but the operational boundary cited here aligns with internal risk assessments conducted under the guidance of the European Federation of Chemical Engineering’s “HarsMeth” methodology. Batches operated outside this window have exhibited a rapid temperature rise to 38 °C within 90 seconds, triggering an automatic interlock that dumps the reactor contents to a kill tank and generates a deviation report with a full corrective and preventive action (CAPA) investigation.